Search research articles
Contact Us
Filters
Showing results (821-830 of 853) with videos related to
Page
of 86
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group
S B Kaye, J Paul, J Cassidy, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The Lancet. Oncology
|
July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity
S M Rudman, D H Josephs, H Cambrook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
Timothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 11, 2020
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2011
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
David S P Tan, Marjan Iravani, W Glenn McCluggage, et al.
Page
of 86
Search research articles
Search
Showing results (821-830 of 853) with videos related to
Sort By:
Page
of 86
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1996
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group
S B Kaye, J Paul, J Cassidy, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The Lancet. Oncology
|
July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|
May 17, 2011
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity
S M Rudman, D H Josephs, H Cambrook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
Timothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 11, 2020
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
Debashis Sarker, Joo Ern Ang, Richard Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2011
Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas
David S P Tan, Marjan Iravani, W Glenn McCluggage, et al.
Page
of 86